T3 Instillation for Acute Respiratory Distress Syndrome
(ARDS+T3 Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
It is hypothesized that instillation of Liothyronine Sodium (T3) into the airspace will be safe, well tolerated, and will increase alveolar fluid clearance and decrease inflammation in patients with ARDS, reflected in improved oxygenation index (OI) and oxygenation saturation index (OSI).
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Is T3 (Liothyronine Sodium) safe for human use?
How is the drug Liothyronine Sodium (T3) unique in treating Acute Respiratory Distress Syndrome?
What data supports the effectiveness of the drug Liothyronine Sodium (T3) for treating acute respiratory distress syndrome (ARDS)?
Research shows that T3 can enhance lung function by improving alveolar fluid clearance, which is important for recovery in ARDS. In animal studies, a reformulated version of T3 was safely administered to the lungs, paving the way for human trials to assess its impact on lung water levels in ARDS patients.5891011
Who Is on the Research Team?
David H Ingbar, MD
Principal Investigator
University of Minnesota
Timothy P Rich, MD
Principal Investigator
University of Minnesota
Ronald A Reikoff, MD
Principal Investigator
University of Minnesota
Are You a Good Fit for This Trial?
This trial is for adults over 18 with ARDS needing ventilators in ICU. They must be able to consent or have a representative who can, and not be pregnant or breastfeeding. Excluded are those allergic to the drug, with thyroid cancer, hyperthyroidism, significant heart disease, or unlikely to follow the study through.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive Liothyronine Sodium (T3) instilled into the airway twice daily for 5 days or until extubation
Follow-up
Participants are monitored for safety and effectiveness after treatment, including oxygenation indices and cardiovascular events
What Are the Treatments Tested in This Trial?
Interventions
- Liothyronine Sodium (T3)
Liothyronine Sodium (T3) is already approved in United States, European Union for the following indications:
- Hypothyroidism
- Myxedema coma
- Thyroid suppression test
- TSH suppression
- Underactive thyroid
- Hypothyroidism
- Myxedema coma
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Minnesota
Lead Sponsor